Oxaliplatin-Associated Takotsubo Cardiomyopathy in a Patient with Metastatic Gastric Cancer: A Case Report.

Autor: Osorio-Toro LM; Specialization Program in Internal Medicine, School of Health, Universidad Santiago de Cali, Santiago de Cali, Colombia.; Research and Education Department, Clínica de Occidente S.A., Santiago de Cali, Colombia.; Genetics, Physiology and Metabolism Research Group (GEFIME), Universidad Santiago de Cali, Santiago de Cali, Colombia., Bonilla-Bonilla DM; Specialization Program in Internal Medicine, School of Health, Universidad Santiago de Cali, Santiago de Cali, Colombia.; Research and Education Department, Clínica de Occidente S.A., Santiago de Cali, Colombia.; Genetics, Physiology and Metabolism Research Group (GEFIME), Universidad Santiago de Cali, Santiago de Cali, Colombia., Escobar-Dávila SL; Research and Education Department, Clínica de Occidente S.A., Santiago de Cali, Colombia.; Department of Medical Oncology, Comprehensive Cancer Center, Clínica de Occidente S.A., Santiago de Cali, Colombia., Quintana-Ospina JH; Specialization Program in Internal Medicine, School of Health, Universidad Santiago de Cali, Santiago de Cali, Colombia.; Research and Education Department, Clínica de Occidente S.A., Santiago de Cali, Colombia., Melo-Burbano LÁ; Specialization Program in Internal Medicine, School of Health, Universidad Santiago de Cali, Santiago de Cali, Colombia.; Research and Education Department, Clínica de Occidente S.A., Santiago de Cali, Colombia.; Genetics, Physiology and Metabolism Research Group (GEFIME), Universidad Santiago de Cali, Santiago de Cali, Colombia., Benitez-Escobar EN; Specialization Program in Internal Medicine, School of Health, Universidad Santiago de Cali, Santiago de Cali, Colombia.; Research and Education Department, Clínica de Occidente S.A., Santiago de Cali, Colombia.; Genetics, Physiology and Metabolism Research Group (GEFIME), Universidad Santiago de Cali, Santiago de Cali, Colombia., Galindes-Casanova DA; Specialization Program in Internal Medicine, School of Health, Universidad Santiago de Cali, Santiago de Cali, Colombia.; Research and Education Department, Clínica de Occidente S.A., Santiago de Cali, Colombia.; Genetics, Physiology and Metabolism Research Group (GEFIME), Universidad Santiago de Cali, Santiago de Cali, Colombia., Daza-Arana JE; Specialization Program in Internal Medicine, School of Health, Universidad Santiago de Cali, Santiago de Cali, Colombia.; Health and Movement Research Group, Universidad Santiago de Cali, Santiago de Cali, Colombia., Rivas-Tafurt GP; Specialization Program in Internal Medicine, School of Health, Universidad Santiago de Cali, Santiago de Cali, Colombia.; Department of Medical Oncology, Comprehensive Cancer Center, Clínica de Occidente S.A., Santiago de Cali, Colombia.
Jazyk: angličtina
Zdroj: Case reports in oncology [Case Rep Oncol] 2023 Aug 14; Vol. 16 (1), pp. 613-620. Date of Electronic Publication: 2023 Aug 14 (Print Publication: 2023).
DOI: 10.1159/000531389
Abstrakt: We present the case of a 64-year-old female with stage IV gastric adenocarcinoma, pulmonary, and abdominal wall metastases, and no history of cardiovascular disease. In palliative care, she received systemic cytotoxic treatment with fluorouracil, leucovorin, oxaliplatin, and docetaxel protocol, which was well tolerated over five cycles. During cycle 6, she presented with cardiovascular symptoms with hemodynamic consequences while receiving oxaliplatin injection without docetaxel or 5-fluorouracil. She was transferred to the emergency department and then to the intensive care unit. She developed no complications during the hospital stay and was discharged after 10 days with preserved systolic function and no structural changes at the myocardial level. The electrocardiogram, echocardiogram, cardiac catheterization, and magnetic resonance imaging findings indicated an oxaliplatin-associated Takotsubo syndrome. The immunochemistry analysis showed PD-L1 expression level TPS: 40% and the foundation one genomic profiling revealed high mutation load, microsatellite instability, and HER2 not found. The patient is currently asymptomatic and on pembrolizumab monotherapy with good tolerance and partial treatment response.
Competing Interests: The authors have no conflicts of interest to declare.
(© 2023 The Author(s). Published by S. Karger AG, Basel.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje